During the past decade, Washington Institute for Coagulation conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 2 clinical trials were completed, i.e. on average, 22.2% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 2 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Washington Institute for Coagulation" #1 sponsor was "Pfizer" with 3 trials, followed by "Washington Institute for Coagulation" with 2 trials sponsored, "American Thrombosis and Hemostasis Network" with 1 trials sponsored, "CSL Behring" with 1 trials sponsored and "Hoffmann-La Roche" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Washington Institute for Coagulation" #1 collaborator was "Genentech, Inc." with 4 trials as a collaborator, "Hemophilia of Georgia, Inc." with 1 trials as a collaborator and "Pfizer" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Washington Institute for Coagulation" are "Hemophilia A" (6 trials), "Hemophilia B" (2 trials), "Acquired Hemophilia A" (1 trials), "Bleeding Disorder" (1 trials) and "Connective Tissue Disorder" (1 trials). Many other conditions were trialed in "Washington Institute for Coagulation" in a lesser frequency.

Most popular intervention types in "Washington Institute for Coagulation" are "Biological" (3 trials), "Drug" (3 trials), "Device" (1 trials), "Genetic" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "AAV5-hFIXco-Padua" (1 trials), "Emicizumab" (1 trials), "Factor IX (FIX)" (1 trials), "PF-06741086" (1 trials) and "PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy" (1 trials). Other intervention names were less common.

The vast majority of trials in "Washington Institute for Coagulation" are 6 trials for "Male" genders and 3 trials for "All" genders.

Currently, there are NaN active trials in "Washington Institute for Coagulation". undefined are not yet recruiting, 5 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Washington Institute for Coagulation, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Washington Institute for Coagulation, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".